Soft-tissue sarcomas account for about 1% of all adult and 15% of all pediatric malignancies. To date, more than 50 different histologic subtypes have been identified. Test your knowledge about sarcoma in our latest quiz.
Advertisement
Soft-tissue sarcomas account for about 1% of all adult and 15% of all pediatric malignancies. To date, more than 50 different histologic subtypes have been identified. Test your knowledge about sarcoma in our latest quiz.
The American Cancer Society notes that the World Health Organization’s current classification system “permits use of MFH as an alternative name.”
Question 3:
Answer and Question 4 on Next Page »
The correct answer is: C. 32 per 100,000 person-years
This was compared with 13 suicides per 100,000 person-years in the general population, according to the study. A higher incidence of suicide was observed in men, white patients, those between the ages of 21–30 and 61–70, patients with cancer of the vertebral column and pelvic bones, and within the first 5 years of cancer diagnosis. The authors concluded that “by identifying at-risk patients, we can hope to reduce the incidence of suicide in this population by providing the treatment that these patients need.”
Question 4:
Answer and Question 5 on Next Page »
The correct answer is: D. Extremities, visceral, retroperitoneum, and trunk
According to the guidelines the most common site is the extremities (43%), followed by visceral (19%), retroperitoneum (15%), and trunk (10%).
Question 5:
Answer on Next Page »
The correct answer is: B. Leiomyosarcoma
One study found that leiomyosarcoma was the most frequently diagnosed subtype in patients with a history of hereditary retinoblastoma, with 78% of the leiomyosarcomas diagnosed 30 or more years after the retinoblastoma diagnosis.
The panel discussed the risk-benefit profile of the Galleri multicancer early detection test, which was evaluated in the NHS-Galleri and PATHFINDER 2 studies.
“Cardiovascular assessment should begin when the patient is being selected for treatment, not after the toxicity emerges,” said Faisal Mehmud, MD, MRCP.
The FDA has approved lirafugratinib for advanced cholangiocarcinoma harboring an FGFR2 fusion or other rearrangement based on the phase 1/2 ReFocus trial.
Meletios A. Dimopoulos, MD, discussed where bispecific antibodies such as teclistamab may fit for patients with relapsed Waldenström macroglobulinemia.
In the LINKER-SMM1 trial, single-agent linvoseltamab produced a 100% overall response rate among evaluable patients with high-risk smoldering multiple myeloma.
Experts preview ASTRO 2026 presentations to watch, including those on SOFT Preop, PSMAgRT, radiosurgery for depression, and AI tools for patient safety.